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Reply
The data from the 3 largest completed trials of homocysteine
lowering with folic acid and vitamin B12 with or without vitamin B6
(VISP [Vitamin Intervention for Stroke Prevention] [1], NORVIT
[Norwegian Vitamin Trial] [2], and HOPE-2 [Heart Outcomes
Prevention Evaluation] [3]) consistently demonstrate no treatment
benefit in patients with established vascular disease. These trials
primarily evaluated white, middle-aged patients exposed to folate-
fortified food (70% in HOPE-2, 100% in VISP) with only mild
increases in homocysteine levels (15 mol/l). We agree that
homocysteine-lowering therapy might potentially still prove to be
beneficial in populations other than those studied—for example, in
Southeast Asian patients where homocysteine levels typically
exceed 15 mol/l related to genetic or dietary factors, as suggested
by Dr. Akhtar. However, subgroup analyses of the NORVIT and
HOPE-2 trials provide useful insights. In 40% of patients in the
NORVIT trial with a baseline homocysteine level above 13 mol/l
(mean homocysteine level was 17.4 mol/l in this subgroup),
homocysteine-lowering therapy provided no benefit. Similarly, no
treatment benefit was observed among patients in the upper fifth of
the baseline homocysteine distribution (19.7 mol/l) in
HOPE-2. It is quite possible that this lack of benefit may be
related to inadequate statistical power in these subgroups. Thus,
whether homocysteine-lowering therapy is going to be beneficial
cannot be answered definitively until prospective, randomized
trials are conducted in these populations. Ongoing large trials that
are currently exploring these issues and the planned meta-analyses
of all trials (12 trials involving about 52,000 participants with
adequate statistical power, 7 in populations without fortification,
and 5 in populations with fortification) (4) might help answer
remaining relevant clinical questions.
With regards to folate therapy and in-stent restenosis, we do
mention in our article (5) (p. 916) that slight, but not significant,
benefits were observed in patients with elevated homocysteine
levels (27.2% vs. 31.7%; p  NS).
A causal link between recent trends toward a lower rate of death
from stroke in the U.S. and Canada and the fortification of food
with folic acid remains speculative, as many other factors may have
contributed to the decline (6).
Finally, we agree with Dr. Akhtar that a major obstacle to
developing tools that address health problems of people in devel-
oping countries is the so-called 10/90 problem, whereby 90% of
health research expenditure is targeted at problems affecting only
10% of the world’s population. Investment in health, both at the
individual country level and at a global level, should therefore be
encouraged to provide the necessary resources to develop these
tools and enhance public health.
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